Dec 7 (Reuters) – Drugmaker Gilead Sciences Inc
said on Thursday it had agreed to acquire privately-held Cell
Design Labs Inc for up to $567 million to boost its CAR-T cancer
drug pipeline.

Read More At Article Source | Article Attribution